NEW YORK (GenomeWeb News) – Foundation Medicine and Memorial Sloan-Kettering Cancer Center today said they are partnering to co-develop a molecular diagnostic tool to match patients who have hematologic cancers with the most appropriate targeted therapies or clinical trials.
The product will be based on Foundation Medicine's technology, methods, and computational algorithms, and will be developed using RNA and DNA sequencing, "to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies," Foundation Medicine and MSKCC said in a statement.
MSKCC will provide its clinical and genomic expertise to the effort.
The new test will be complementary to FoundationOne, Foundation Medicine's product launched last year for the genomic profiling of solid tumors, the Cambridge, Mass.-based company said. FoundationOne also provides reports to help physicians match patients with targeted therapies or clinical trials that are most appropriate for them.
The new test, anticipated to be launched by the end of the year, similarly will allow physicians to match genomic alterations with the most suitable targeted treatments for their patients.
Foundation Medicine plans to commercialize the test in the US and internationally.